Announcements - OBI Pharma 台灣浩鼎

2025.Jun.06

OBI's GlycOBI has attracted an international collaborator, TegMine Therapeutics, for the co-development of novel Antibody-Drug Conjugates

2025.May.20

Announcement on behalf of OBIGEN of resolution to lift the non-competition restrictions for directors

2025.May.20

Announcement on behalf of OBIGEN of important resolutions of 2025 Annual Shareholders’ meeting and accumulated losses amounting to 50% of paid-in capital

2025.May.12

The Board of Directors resolved to issue new common shares by private placement

2025.May.12

The Company's Board of Directors resolved to convene the 2025 Annual General Shareholders' Meeting (Additional matters)

2025.May.12

The BOD resolved to rename the Audit Committee to the Audit and Risk Management Committee

2025.May.12

The BOD resolved to rename the Remuneration Committee to the Remuneration and Nomination Committee

2025.May.12

Announcement of the Consolidated Financial Statements for the first quarter of 2025 were approved by the Board of Directors

2025.May.12

Announcement on behalf of Amaran that its institutional director changes its representative

2025.May.12

Announcement on behalf of Amaran of the resignation of its representative of institutional director

News

Latest News

Events

Latest events